Health Economics & Outcomes Research: Group Structure and Staffing

STUDY OVERVIEW

Health Outcomes is becoming an integral part of the biopharmaceutical lexicon. Organizations understand that payers and consumers want products that provide positive outcomes for patients' health. One of the key issues facing companies as they establish and expand their Health Outcomes organizations is how to structure and staff these important groups.

To highlight current approaches around Health Outcomes group structure and staffing, Best Practices, LLC conducted a primary research project to inform leaders involved in Health Outcomes operations at biopharmaceutical companies.

This study provides Health Outcomes insights such as:

• The maturity level of Health Outcomes organizations
• The organizational structure and leadership of Health Outcomes organizations
• Resource levels for Health Outcomes groups

• Longevity of Health Outcomes Groups
• Health Outcomes Leadership
• Health Outcomes Reporting Structure
• Health Outcomes Group Staffing
  

• Length of time a Health Outcomes program has been in place at company
• Title of person who heads the Health Outcomes group
• To what function does the Health Outcomes group report to
• Number of FTEs working in HO group and percentage who are in field-based roles
  

• Reporting Structure: More than half of the benchmark class companies’ HO groups report to Medical Affairs. Meanwhile, one-fourth of the benchmark class doesn’t have a traditional reporting structure, and report to departments such as global value, access and policy, or market access.

Twenty-three survey responses from Medical Affairs leaders at 23 top life-science companies. Segments were created for all companies, company size and Health Outcomes maturity level. Additional deep-dive interviews were conducted with five selected Medical Affairs executives.

Industries Profiled:
Biotech; Pharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Roche; AstraZeneca; Bayer; Eli Lilly; Merck; Sanofi; Boehringer Ingelheim; Astellas; Baxter Healthcare; Eisai; Upsher-Smith; Insys Therapeutics; Onyx Pharmaceuticals; Lundbeck; Incyte; Jazz Pharmaceuticals; Merz Pharma; UCB Pharma; ProStrakan; Purdue Pharma; MannKind Corporation; Axon Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.